NBCC’s advocacy has resulted in more than $3.9 billion federal dollars for breast cancer research.
Breast cancer accounts for nearly a quarter of all cancers in women worldwide.
The DOD BCRP was created as a result of NBCC’s “$300 Million More” campaign to increase federal funding for breast cancer research.
NBCC will hold two Project LEAD Institute sessions for the summer of 2022, in La Jolla, CA. Applications for both sessions are now open
Save the Date for NBCC Advocate Leadership Summit, Become a Research Advocate, And More!
The National Breast Cancer Coalition (NBCC) and its hundreds of member organizations around the country would like to thank lead Senators Chris Murphy (D-CT) and Joni Ernst (R-IA) as well as original cosponsors Blumenthal (D-CT), Blunt (R-MO), Capito (R-WV), Hassan (D-NH), Shaheen (D-NH), Smith (D-MN), Tester (D-MT), and Van Hollen (D-MD) for supporting this vital legislation.
We all want new treatments to “work” for breast cancer patients. For the National Breast Cancer Coalition (NBCC), that means the investigational therapy will significantly prolong overall survival (OS) without adverse impact on quality of life. We expect that the evidence of that benefit will be shown by well-designed, well-conducted prospective randomized clinical trials, sufficiently designed to support that result. Unfortunately, that has not been the case with TECENTRIQ® (atezolizumab) in first-line treatment of advanced or metastatic triple-negative breast cancer (TNBC).